Bio-Rad Laboratories, Inc.
BIO- Exchange
- NYSE
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0000012208
No open-market purchases or sales by Bio-Rad Laboratories, Inc. insiders were filed in the last 90 days; 403 institutions reported holding it in 13F filings for Q2 2026, worth $5.70B in total; no superinvestor holds it.
Other share classesBIO.B
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +8 vs. previous quarter
- 403
- 13F valueReported value at the end of Q2 2026
- $5.70B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $2.58B
- +0.7% year over year
- Net income, FY2025
- $759.9M
- No comparable prior period
- Free cash flow, FY2025
- $374.6M
- +29.4% year over year
- Revenue, Q3 FY2026
- $656.4M
- +0.5% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.16M
- Shares sold short
- Change
- +59.4K
- +5.4% vs. previous
- Days to cover
- 5.07
- At average daily volume
Superinvestors holding BIO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding BIO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Bio-Rad Laboratories, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 (view filing) | May 11 | 2 days | Engelhardt Eva AnetteEVP, President, CDG | SSaleBio-Rad A Common Stock | −550 | $246.54 | −$135.6K | −61.4%346 after | |
| Nov 10, 2025 (view filing) | Nov 6 | 4 days | Barry JamesEVP, President, LSG | SSaleBio-Rad A Common Stock | −699.87 | $306.18 | −$214.3K | −57.9%509.68 after | |
| Mar 18, 2025 (view filing) | Mar 14 | 4 days | Crowley MichaelEVP, GBL Commercial Operations | SSaleBio-Rad A Common Stock | −3.00K | $247.06 | −$741.2K | −26.9%8.17K after | |
| Sep 10, 2024 (view filing) | Sep 6 | 4 days | Last Andrew J.EVP, Chief Operating Officer | SSaleBio-Rad A Common Stock | −3.00K | $329.94 | −$989.8K | −28.4%7.56K after | |
| Sep 4, 2024 (view filing) | Sep 4 | Same day | Barry JamesEVP, President, LSG | SSaleBio-Rad A Common Stock | −623 | $330.49 | −$205.9K | −81.0%146.56 after | |
| Jun 14, 2024 (view filing) | Jun 13 | 1 day | Crowley MichaelEVP, GBL Commercial Operations | SSaleBio-Rad A Common Stock | −369 | $281.91 | −$104.0K | −5.3%6.57K after | |
| May 1, 2024 (view filing) | May 3, 2023 | 364 daysLate | Schwartz Steven D10% Owner | SSaleBio-Rad A Common Stock | −320 | $463.86 | −$148.4K | −17.6%1.50K after | |
| Feb 29, 2024 (view filing) | Feb 28 | 1 day | Ernst Timothy SEVP, General Counsel & Sec | SSaleBio-Rad A Common Stock | −2.50K | $330.55 | −$826.4K | −42.4%3.40K after | |
| Feb 28, 2024 (view filing) | Feb 27 | 1 day | Crowley MichaelEVP, GBL Commercial Operations | SSaleBio-Rad A Common Stock | −3.00K | $336.00 | −$1.01M | −30.2%6.94K after | |
| Dec 12, 2023 (view filing) | Dec 12 | Same day | Wright DaraEVP, President, CDG | SSaleBio-Rad A Common Stock | −1.20K | $299.16 | −$359.0K | −44.5%1.50K after |
Top 10 13F holders, Q2 2026
See all 403 holdersThe largest institutional positions in Bio-Rad Laboratories, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| First Eagle Investment Management, LLC | 2,606,219 | $765.2M | 1.26% | +3,447+0.1% | Added |
| BlackRock, Inc. | 1,698,929 | $498.8M | 0.01% | +18,869+1.1% | Added |
| Dimensional Fund Advisors LP | 944,548 | $277.3M | 0.05% | −144,775−13.3% | Reduced |
| Vanguard Capital Management LLC | 826,972 | $242.8M | 0.01% | −4,193−0.5% | Reduced |
| Ariel Investments, LLC | 816,751 | $239.8M | 2.39% | +30,790+3.9% | Added |
| Vanguard Portfolio Management LLC | 816,198 | $239.6M | 0.01% | −12,988−1.6% | Reduced |
| Earnest Partners LLC | 580,752 | $170.5M | 0.61% | −7,979−1.4% | Reduced |
| State Street Corp | 571,762 | $167.9M | 0.00% | +12,192+2.2% | Added |
| Bank of America Corp | 490,412 | $144.0M | 0.01% | +45,455+10.2% | Added |
| Capital World Investors | 462,457 | $135.8M | 0.02% | +12,457+2.8% | Added |
Holders of 5% or more of BIO
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Bio-Rad Laboratories, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Schwartz Norman D | 13D/A | 97.20%4.93M shares | +82.60 ppfrom 14.60% | Oct 28, 20254 filings | Oct 30, 2025 | SEC |
| Schwartz Alice N | 13D/A | 12.30%2.73M shares | – | Apr 11, 20222 filings | Jul 18, 2025 | SEC |
| First Eagle Investment Management, LLC | 13G/A | 11.40%2.53M shares | +1.40 ppfrom 10.00% | May 5, 20253 filings | Aug 6, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 7.40%1.62M shares | – | Oct 22, 20243 filings | Oct 17, 2025 | SEC |
Politician trades
All politician trades in BIO3 members of Congress reported 11 trades in Bio-Rad Laboratories, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Oct 10, 2023 |  Lois Frankel House · FL | Sell | $1K-$15K |
| Jul 28, 2023 | Lois Frankel House · FL | Buy | $1K-$15K |
| Jul 28, 2023 | Lois Frankel House · FL | Buy | $1K-$15K |
| Dec 29, 2022 |  Susie Lee House · NV | Sell | $1K-$15K |
| Apr 8, 2022 |  Tommy Tuberville Senate · AL | Sell (full) | $1K-$15K |
House · FL · Oct 10, 2023
Sell$1K-$15K
House · FL · Jul 28, 2023
Buy$1K-$15K
House · FL · Jul 28, 2023
Buy$1K-$15K
House · NV · Dec 29, 2022
Sell$1K-$15K
Senate · AL · Apr 8, 2022
Sell (full)$1K-$15K